Not medical advice. Talk to your provider before using any peptide. Full disclaimer
Thymosin Beta-4
Beginner tier: 750 mcg, 3x/week · 9w on / 6w off · community consensus
Also known as: Tb4, TB4, Tβ4
In two Phase II ulcer trials, topical thymosin beta-4 sped healing by almost a month in patients whose wounds closed, though complete healing in the pressure ulcer trial matched placebo. Full-length Tb4 is a 43-amino-acid protein and the body's primary G-actin sequestering molecule, controlling cell migration, tissue repair, and angiogenesis through multiple functional domains. The separate Ac-SDKP region adds cardioprotective and anti-fibrotic activity that the shorter TB-500 fragment lacks entirely. Athletes, post-surgical patients, and integrative medicine practitioners use Tb4 for accelerated soft tissue healing, reduced scarring, and systemic anti-inflammatory support. Two Phase I safety trials in healthy volunteers found no dose-limiting toxicities. One reached 1,260 mg IV [1]; the other stopped at 25 mcg/kg [2].
What Is Thymosin Beta-4?
In two Phase II ulcer trials, topical thymosin beta-4 sped healing by almost a month in the patients whose wounds did close (PMID 23050815 (opens in a new tab)). Complete healing in the pressure ulcer trial, though, was no higher than placebo: 14.8% vs 16.7% by day 84 (NCT00382174). Thymosin beta-4 (Tb4, CAS 77591-33-4) is a 43-amino-acid protein with a molecular weight of approximately 4,921 Da.
Tb4 is the most abundant actin-sequestering protein in human cells. It locks G-actin monomers in place, which controls when and where cells migrate, divide, and differentiate. That single mechanism feeds into wound closure, blood vessel formation, and progenitor cell activation. The N-terminal Ac-SDKP tetrapeptide (released by enzymatic cleavage) adds a second layer: anti-fibrotic and cardioprotective signaling that reduces scar tissue and protects cardiomyocytes from oxidative damage.
In practice, the community uses Tb4 primarily for athletic soft tissue injury recovery (tendons, ligaments, muscles) and post-surgical wound healing. The typical loading protocol runs 2 to 2.5 mg subcutaneous, two to three times per week for 6 weeks, followed by weekly maintenance. Stacking with BPC-157 is the dominant community approach; the two cover different healing phases through separate signaling pathways.
Research status as of October 2026: two independent Phase I safety trials found IV Tb4 well tolerated. One went up to 1,260 mg [1]; the other topped out at 25 mcg/kg [2]. Phase II data exists for wound healing and dry eye. Only eye drops (RGN-259) reached Phase III; no injected Tb4 trial has. In SEER-1, a neurotrophic keratopathy trial, 6 of 10 treated patients healed fully after 4 weeks vs 1 of 8 on placebo, short of significance (p=0.0656, PMID 36613994 (opens in a new tab)). A 2025 cardiac RCT (n=96 STEMI patients) found significant infarct reduction in the early-treatment subgroup (n=43) but missed significance in the full cohort. No FDA approval exists for any indication. Tb4 is not on the 503A bulks list, and its TB-500 fragment is listed as withdrawn on FDA's Category 2 page (current as of April 22, 2026).
How Thymosin Beta-4 Works
Tb4 sequesters G-actin monomers. That sounds abstract until you consider what actin polymerization controls: cell migration, proliferation, differentiation, and wound closure. By regulating the pool of available G-actin, Tb4 is a master switch for tissue repair timing.
The central LKKTETQ domain (amino acids 17 to 23, shared with the TB-500 fragment) binds actin directly. This promotes cell motility and angiogenesis at injury sites. Blood vessel formation accelerates nutrient and oxygen delivery to damaged tissue.
Full-length Tb4 carries something the fragment does not. The N-terminal Ac-SDKP tetrapeptide, released by enzymatic cleavage, provides distinct anti-fibrotic signaling. It attenuates inflammatory macrophage infiltration, reduces fibroblast overactivity, and protects cardiomyocytes from oxidative stress. ACE normally degrades Ac-SDKP; patients on ACE inhibitors may see raised Ac-SDKP levels and stronger anti-fibrotic effects (a clinically relevant interaction).
Tb4 also activates integrin-linked kinase (ILK). This drives cardiac progenitor cell activation and epicardial cell migration. After tissue injury, platelets and macrophages release Tb4 to protect surrounding cells from secondary damage. A 2025 study tied this repair to ErbB2 in mice; in its 96-patient STEMI trial, only the group dosed within 8 hours of PCI had significantly smaller infarcts (Zhang et al., Cardiovasc Res 2025, PMID 41229390 (opens in a new tab)).
Thymosin Beta-4 Benefits
- Thymosin beta-4 benefits center on tissue repair, anti-fibrotic activity, and systemic healing support across multiple organ systems.
- Wound healing acceleration in Phase II data: topical Tb4 sped healing by almost a month in patients whose ulcers closed (PMID 23050815 (opens in a new tab)), though complete pressure ulcer healing matched placebo (14.8% vs 16.7% at day 84, NCT00382174).
- Cardioprotective Ac-SDKP domain that TB-500 (7aa fragment) does not contain; this tetrapeptide reduces fibrosis and protects cardiomyocytes from oxidative injury [3][4].
- Community users consistently report faster return to training after tendon, ligament, and muscle injuries within 2 to 4 weeks of loading, across an estimated 200 to 500 Reddit threads.
- Reduced scar tissue formation at chronic injury sites through direct anti-fibrotic signaling via macrophage modulation and fibroblast suppression.
- Neuroprotective properties observed in preclinical traumatic brain injury models, with Tb4 reducing inflammation and promoting neural cell survival [5].
- Systemic anti-inflammatory effect reported by users within the first 1 to 2 weeks of loading; the body's own platelets and macrophages release Tb4 after tissue damage, and exogenous dosing amplifies this endogenous response.
Thymosin Beta-4: Science vs Community Consensus
Phase I safety established in two independent healthy volunteer trials (IV, up to 1,260 mg in, and up to 25 mcg/kg in)[1][2].
Read the evidence (key study, limitations)
Phase II efficacy data: wound healing (pressure ulcers: complete healing 14.8% vs 16.7% placebo by day 84, NCT00382174; faster closure in healers, PMID 23050815 (opens in a new tab)), dry eye, venous ulcers. Phase III trials tested RGN-259 eye drops. ARISE-2 and ARISE-3 in dry eye completed but missed their registered primary endpoints (NCT02974907, NCT03937882). SEER-1 in neurotrophic keratopathy stopped early after 18 patients (registry: business decision; paper: slow recruitment). It missed its primary endpoint: 6 of 10 healed vs 1 of 8 on placebo (p=0.0656; NCT02600429, PMC9820614). 2025 cardiac RCT (n=96 STEMI) showed significant infarct reduction in early-treatment subgroup (n=43) but not full cohort. No FDA approval for any indication as of October 2026.
Cardiovascular Research 2025, Vol 121(17): Randomized, double-blind, placebo-controlled RCT of rhTβ4 in 96 STEMI patients post-PCI. Early-treatment subgroup (rhTβ4 within 8h post-PCI, n=43): significant infarct area reduction vs placebo at 90 days; ErbB2-dependent mechanism confirmed in parallel murine I/R model. Full cohort (n=96): non-significant. Most clinically significant human cardiac efficacy signal to date. PMID 41229390
No FDA approval for any indication, and no Phase III trial has tested injected Tβ4. Phase III ophthalmic trials missed or inconclusive on primary endpoints. 2025 cardiac RCT full cohort non-significant; early-treatment subgroup result requires confirmation. Long-term safety data absent. Tβ4 is not on the 503A bulks list; its TB-500 fragment is listed as withdrawn on FDA's Category 2 page (current as of April 22, 2026). Full-length 43aa vs 7aa TB-500 fragment frequently conflated in community reports, confounding evidence interpretation. SC pharmacokinetics formally uncharacterized: all PK data is IV-derived.
Strongly endorsed for athletic soft tissue injury (tendons, ligaments, muscles) and post-surgical wound healing.
Read the reports (what users report 6, common issues 6)
Most community discussion conflates full-length 43aa Tβ4 with TB-500 (7aa fragment): protocols labeled "TB-500" may or may not reflect full-length product. Full-length Tβ4 is considered by advanced users to have broader benefit (cardiac, anti-fibrotic, immunomodulatory) but is harder to source and verify.
- Faster return to training after tendon, ligament, and muscle injuries: commonly noted within 2–4 weeks of loading
- Reduced localized pain and inflammation at injury site
- Improved range of motion and joint pliability during loading phase
- Wound healing acceleration (overlaps with Phase II clinical data for pressure ulcers)
- Systemic anti-inflammatory effect felt within first 1–2 weeks of loading
- Reduced scar tissue formation at chronic injury sites
- Cost: full-length 43aa more expensive than TB-500 fragment (~$8–16/mg vs ~$5–8/mg); typical 8-week cycle (20 mg) costs $90–$320 at research prices
- Labeling confusion: must verify "43aa" on label; many products labeled "TB-500" contain the 7aa fragment without distinguishing it from full-length
- Reduced availability due to FDA enforcement actions (2024–2026)
- No community consensus on dosing frequency (daily vs 2–3x/week): creates protocol confusion
- Flu-like symptoms and fatigue in first 1–2 weeks of loading phase
- COA with mass spectrometry needed to confirm identity but rarely checked by users: mislabeled products common
Science evidence is concentrated in ophthalmic (Phase III), wound healing (Phase II), and cardiac (Phase II). Community uses Tβ4 primarily for athletic soft tissue injury: mechanistically plausible extrapolation from wound healing evidence but not directly studied in RCT format. Both science and community converge on a healing/regenerative use case. Dosing frequency diverges: clinical trials used structured loading regimens; community standard is 2–3x/week SC. Doses are broadly comparable when expressed as weekly totals.
Thymosin Beta-4 Dosage Guide
First thing: make sure your product is actually 43 amino acids. The community conflates Tb4 with TB-500 constantly, and product labels don't help. If your COA doesn't show a molecular weight near 4,921 Da on mass spectrometry, you probably have the 7aa fragment (843 Da). HPLC purity alone can't tell the difference.
Reconstitution math for common vial sizes. A 5 mg vial plus 1 mL bacteriostatic water gives you 5 mg/mL (5,000 mcg/mL). On a U-100 insulin syringe, each unit equals 50 mcg. So 2,000 mcg (a standard loading dose) is 40 units; 2,500 mcg is 50 units; 1,500 mcg is 30 units. For a 2 mg vial plus 1 mL BAC water, you get 2 mg/mL; 750 mcg (beginner tier) is 37.5 units.
Store reconstituted vials refrigerated at 2 to 8 degrees C and use within 2 to 3 weeks. Lyophilized powder keeps for up to 24 months refrigerated. Use bacteriostatic water, not sterile saline (saline shortens shelf life after reconstitution).
The short half-life (about 2 hours IV) is why daily or frequent dosing makes sense. But the dominant community convention is 2 to 3 times per week at higher doses; either approach can be justified, and the 2 to 3x/week schedule is more practical.
Cycling Protocol
Loading phase: full dose 3x/week for 6-12 weeks. Then maintenance: half dose 1-2x/week. All protocols run 8-12 weeks. Standard community and integrative medicine protocols recommend 6 weeks off after each cycle for receptor sensitivity recovery.
Community and integrative medicine protocols recommend 6 weeks off after each cycle based on receptor sensitivity recovery: sustained Tβ4 exposure may downregulate progenitor cell responsiveness and actin-binding pathway signaling. The 6-week off period also provides a window to objectively assess healing progress before reinitiation, and reduces theoretical risk of continuous angiogenic promotion in the context of any undetected occult malignancy. The short IV half-life (~2h) ensures rapid plasma clearance, but downstream cellular effects (progenitor activation, angiogenic signaling) may persist significantly longer.
- No further injury healing progress at week 8 despite continued dosing: diminishing returns indicate cycle completion
- Increasing injection site nodule formation despite site rotation: suggests local inflammatory sensitization
- Return of fatigue or flu-like symptoms mid-cycle after initial resolution: possible immune response to the peptide
- Injury fully resolved: no indication for continued loading; transition to off-cycle
Or use the universal Peptide Calculator for any peptide.
Thymosin Beta-4 Protocols by Goal
Expected: Reduced pain and inflammation at injury site by weeks 2–3; improved tissue pliability and range of motion by weeks 4–6; accelerated return to full training by weeks 8–12. Community reports strongly positive for tendon and ligament injuries.
Monitor: No specific labs required for healthy adults on short cycles. Monitor injection sites for nodule formation (rotate sites more frequently if nodules appear). Discontinue if fever >100.4°F or skin rash/hives develop.
How to Use Thymosin Beta-4
- 1Step 1
Wash hands thoroughly and wipe vial tops with an alcohol swab.
- 2Reconstitute: add 1 mL bacteriostatic water to a 5 mg vial
Let the water run down the inside wall of the vial. Do not shake; swirl gently until dissolved. This gives you 5 mg/mL (50 mcg per unit on a U-100 syringe).
- 3Draw your dose
For a 2,000 mcg loading dose, pull to the 40-unit mark on a U-100 insulin syringe. For 2,500 mcg, pull to 50 units. For 1,500 mcg (wound healing protocol), pull to 30 units.
- 4Step 4
Choose an injection site on the abdomen (2 inches from the navel) or outer thigh. Tb4 is systemic; you do not need to inject near the injury site.
- 5Step 5
Pinch the skin, insert the needle at a 45-degree angle (29 to 31 gauge, 0.5-inch needle), and inject slowly over 10 or more seconds.
- 6Rotate injection sites at every injection
Do not reuse the same spot within the same week. This prevents nodule formation.
- 7Timing: morning or post-workout
No specific meal timing required.
- 8Loading phase: dose 2 to 3 times per week for 6 weeks
Maintenance: reduce to once per week for 6 more weeks. Then take 6 weeks off before restarting.
- 9Step 9
Store reconstituted vial in the refrigerator (2 to 8 degrees C). Use within 2 to 3 weeks of reconstitution.
Alternative Routes
Community: 2–5 mg SC per injection, 2–3x/week. No formal human bioavailability comparison vs IV. All PK data (PMID 20536472) is entirely IV-derived. SC absorption rate and peak plasma levels are unknown in humans.
Abdomen or thigh. Systemic effect: no need to inject near injury site. Use 29–31G needle. Rotate sites at every injection. Reconstitute with bacteriostatic water (not sterile saline: shorter shelf life with saline).
Phase I trials used 42–1,260 mg IV as single and 14 daily doses (PMID 20536472, far above any community SC dose) and 0.05–25 mcg/kg IV (PMID 34346165). Registered phase 2 STEMI trials: 0.25 to 2.0 mcg/kg IV once daily for 7 days after PCI (NCT05485818, NCT05984134). Half-life 0.95–2.1h (dose-dependent) characterized only via IV route.
Used in clinical trials for controlled PK characterization and cardiac applications. SC remains the only practical community route.
RGN-259 protocol: 0.1% Tβ4 ophthalmic drops 5x/day × 4 weeks (Phase III SEER-1 and SEER-2 design). Topical ophthalmic route does not provide systemic healing effects. Engineered tandem tTβ4 (IOVS Nov 2025, PMC12636994) shows 7-fold improved corneal epithelial migration vs standard monomer: next-generation formulation not yet in clinical trial.
RGN-259 by RegeneRx Biopharmaceuticals, not FDA-approved as of October 2026. Not available as a consumer product. ARISE dry eye Phase III series: inconclusive. SEER-2, a Phase 3 trial in neurotrophic keratopathy (NCT05555589), is listed as recruiting.
Thymosin Beta-4 Stacking Protocols
Works With
The dominant healing stack. BPC-157 acts through nitric oxide signaling and growth hormone receptor modulation; Tβ4 acts through actin dynamics and progenitor cell activation: complementary mechanisms covering different healing phases. BPC-157 targets early inflammatory resolution; Tβ4 drives angiogenesis and cellular migration.
BPC-157 250–500 mcg SC daily + Tβ4 2–2.5 mg SC 2x/week (loading 6 weeks) → Tβ4 2 mg 1x/week (maintenance 4–6 weeks). 6 weeks off after cycle.
Copper peptide adds anti-inflammatory signaling, collagen synthesis promotion, and angiogenesis support. Commonly added for wound healing or skin repair to complement Tβ4 anti-fibrotic and cellular migration effects.
GHK-Cu 1–2 mg topical or SC daily alongside Tβ4 loading protocol for wound or skin healing goals.
Short tripeptide with anti-inflammatory properties. Community users add KPV for additional systemic or gut anti-inflammatory coverage alongside Tβ4, particularly for systemic inflammation goals.
KPV 500 mcg–1 mg SC or oral daily alongside Tβ4 protocol.
Avoid
Directly opposes Tβ4 mechanism of action. Anti-VEGF therapies block the angiogenesis that Tβ4 actively promotes. Concurrent use is mechanistically contradictory and may negate therapeutic effect of both agents.
Do not combineTβ4 promotes angiogenesis and may increase bleeding risk at healing sites. Clinical significance uncertain but additive bleeding risk is a real concern, particularly post-surgical or with active wound healing.
Corticosteroids suppress the inflammatory cascade that Tβ4 modulates. Concurrent systemic corticosteroid use may blunt Tβ4 healing response by suppressing the immune signaling Tβ4 requires to drive tissue repair.
Tβ4 modulates immune cell migration and macrophage activity. Effect of concurrent immunosuppressive therapy on Tβ4 activity is unknown. Use with caution in transplant patients or those on chronic immunosuppression.
Estimated Cost
Pricing updated 2026-04-09
Thymosin Beta-4 Side Effects
The most serious concern with Tb4 is its relationship to cancer biology. Tb4 promotes angiogenesis, cell migration, and proliferation. All three processes can support tumor growth and vascularization. Some in vitro studies show Tb4 upregulation in tumor tissue; others show anti-tumor effects. Phase I and II trials found no cancer-promoting signals at tested doses, but long-term human data does not exist. Active cancer or personal cancer history is a firm contraindication.
Published safety data comes from two Phase I trials in healthy volunteers. The IV study [1] tested single doses from 42 mg to 1,260 mg and reported no dose-limiting toxicities. Adverse events were infrequent and rated mild to moderate. The Chinese Phase I study [2] confirmed tolerability in a separate population. Total human safety database for injectable Tb4 is small (fewer than 200 participants across all trials combined).
Community-reported side effects during loading phase (weeks 1 to 2):
Fatigue and flu-like symptoms are the most commonly flagged issue. Users describe 3 to 7 days of mild malaise during the initial loading period. This typically resolves by week 2 to 3. If fatigue persists beyond two weeks or fever exceeds 100.4 degrees F, reducing dose or stopping is appropriate.
Headache occurs at moderate frequency. Mild nausea and lightheadedness are less common but reported.
Injection site reactions include redness, mild swelling, and nodule formation. Nodules develop from repeated injection at the same site. Rotating locations at every injection and using 29 to 31 gauge needles reduces this risk.
Occasional mild water retention has been noted during maintenance phases.
Contraindications: active cancer or cancer history (angiogenic risk), pregnancy or breastfeeding (no safety data), active systemic infections (immune modulation concern), known hypersensitivity to Tb4, and concurrent anti-VEGF therapy (directly opposes mechanism).
Drug interactions worth knowing: anticoagulants (warfarin, heparin, DOACs) may carry additive bleeding risk at healing sites. ACE inhibitors block Ac-SDKP degradation and may potentiate anti-fibrotic effects. Anti-VEGF biologics (bevacizumab, ranibizumab) are contraindicated. Immunosuppressants have unknown interaction profiles with Tb4 immune modulation.
Stop dosing and consult a physician if you develop persistent fever, skin rash, hives, signs of anaphylaxis, or any new suspicious mass or lump.
Common Issues & Solutions
No healing response by week 3: Verify product is full-length 43aa (not 7aa TB-500 fragment): check the COA for mass spectrometry confirming molecular weight ~4,921 Da. The 7aa fragment (~843 Da) may provide less benefit for non-angiogenic healing goals.
Fatigue and flu-like symptoms in week 1–2: Expected during loading phase from immune modulation and angiogenic signaling initiation. Typically resolves by week 2–3. If persistent beyond 2 weeks or fever >100.4°F develops, reduce dose or discontinue.
Injection site nodules forming: Rotate injection sites at every injection (do not reuse same location within same week). Use 29–31G needle and inject slowly over 10+ seconds. Nodules indicate local SC trauma from site overuse.
Product uncertainty (post-2026 enforcement): FDA enforcement actions shrank the market. Only a batch-specific third-party COA confirms what a vial holds. If label says "TB-500" without "43aa," assume it is the 7aa fragment.
ACE inhibitor interaction: If taking an ACE inhibitor, ACE normally degrades Tβ4's Ac-SDKP fragment. ACE inhibition elevates Ac-SDKP levels and may potentiate anti-fibrotic effects: potentially beneficial but uncharacterized at community doses. Inform prescribing physician.
Ask AI about this page
Ask AI for a second opinion on Thymosin Beta-4 dosing and side effects
Contraindications
- Active cancer or personal history of cancer: Tb4 promotes angiogenesis and cell proliferation, which may support tumor growth and vascularization
- Pregnancy or breastfeeding: no safety data available in pregnant or lactating individuals
- Active systemic infections: enhanced cell migration and immune modulation could theoretically complicate infection management
- Known hypersensitivity to thymosin beta-4 or any component of the formulation
- Concurrent use of anti-VEGF therapies (bevacizumab): directly opposes Tb4 angiogenic mechanism
Drug Interactions
- Anticoagulants (warfarin, heparin, DOACs): Tb4 promotes angiogenesis and may increase bleeding risk at healing sites
- ACE inhibitors: ACE degrades the Ac-SDKP fragment of Tb4; inhibiting ACE may increase Ac-SDKP levels and potentiate anti-fibrotic effects
- Anti-VEGF therapies (bevacizumab, ranibizumab): directly opposes Tb4 mechanism of action; concurrent use is contraindicated
- Immunosuppressants: Tb4 modulates immune cell migration and macrophage activity; effect on immunosuppressive therapy is unknown
- Other angiogenic healing peptides (BPC-157, TB-500): additive angiogenic effects; monitor closely when stacking
- Warfarin / Anticoagulants (heparin, DOACs)
- Tβ4 modulates immune cell migration and macrophage activity. Effect of concurrent immunosuppressive therapy on Tβ4 activity is unknown. Use with caution in transplant patients or those on chronic immunosuppression.
Product Quality
Three compounding risk vectors: 1) Mislabeling: 7aa TB-500 fragment (~843 Da) frequently sold as full-length 43aa Tβ4 (~4,921 Da), or vice versa; amino acid count must be confirmed by mass spectrometry, not HPLC alone. 2) Regulatory squeeze: FDA enforcement has severely contracted the market. 3) No compounding route: Tβ4 is not on the 503A bulks list (21 CFR 216.23).
- A third-party COA needs mass spectrometry (MS): HPLC purity alone cannot distinguish 43aa from 7aa fragment
- Confirm molecular weight on COA: 43aa full-length Tβ4 = ~4,921 Da; TB-500 7aa fragment = ~843 Da
- Reject any product labeled only "TB-500" without "43aa" stated explicitly: default assumption is 7aa fragment
- Research-grade pricing for verified 43aa: ~$8–16/mg; pricing significantly below this range is a red flag for mislabeled 7aa product
- After 2026 FDA enforcement shrank the market, only a current batch-specific COA counts: not a generic certificate from prior years
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Echocardiogram | Baseline and 90-day follow-up (cardiac-indication use only) | EF ≥55%; no new wall motion abnormalities |
| BNP / NT-proBNP | Baseline and monthly (cardiac-indication use only) | BNP <100 pg/mL; NT-proBNP <125 pg/mL (age-adjusted) |
| CBC (Complete Blood Count) | Baseline only for higher-risk users (cancer history, immunosuppression) | Not listed |
| Injection site self-assessment | Each injection (self-monitoring) | Not listed |
Tβ4 is being investigated for cardiac repair. Monitor ejection fraction and wall motion for cardiac-indication users; provides efficacy evidence and detects adverse events in higher-risk populations.
Biomarker for cardiac stress and heart failure. Tβ4 reduces NT-proBNP in murine cardiac injury models (IJMS 2025). Provides objective marker of cardiac status during cardiac-indication protocols.
Tβ4 promotes cell proliferation and angiogenesis. CBC provides reference baseline in populations where additive proliferative signaling could theoretically be a concern.
Monitor for nodule formation (site overuse), increasing redness/warmth (infection), or skin changes indicating allergic reaction. Early detection prevents nodule complications and infection.
Thymosin Beta-4 Before and After
Loading phase begins with daily dosing. Due to the short half-life, steady-state levels are reached quickly. Early anti-inflammatory effects may be noticeable. Mild fatigue or headache possible during adjustment.
Continued loading phase. Angiogenesis and tissue repair processes accelerate. Noticeable reduction in pain and inflammation around injured areas. Improved flexibility and range of motion.
Transition to maintenance dosing (half dose daily or every other day). Significant healing progress in soft tissue and dermal wounds. Reduced scar tissue formation at injury sites.
Maintenance phase continues. Sustained healing support and anti-fibrotic activity. Evaluate progress and consider cycling off. Resume loading if new injury occurs.
What to Expect
Weeks 1 to 2: Loading Begins. Daily or 2 to 3x/week dosing at full dose gets plasma levels up quickly given the roughly 2-hour IV half-life. Anti-inflammatory effects kick in through macrophage modulation and Ac-SDKP signaling. Most users feel mild fatigue and occasional flu-like symptoms between days 3 and 7. Some notice reduced pain at the injury site by the end of week 2. Others feel nothing yet; the loading effects are cumulative, not immediate.
Weeks 3 to 4: Angiogenesis and Repair Pick Up. New blood vessel formation at injury sites increases oxygen and nutrient delivery. Progenitor cells are migrating and differentiating. Community reports commonly describe meaningful pain reduction, less swelling, better joint mobility, and improved sleep quality. Some users note surprisingly fast resolution of injuries that had been chronic for months. DOMS recovery improves for strength athletes.
Weeks 5 to 6: Peak Loading Effect. In Phase II ulcer trials, topical Tb4 sped healing by almost a month in patients whose wounds closed (PMID 23050815 (opens in a new tab)). Weeks 5 to 6 are the transition window; many users drop to maintenance dosing (2 mg once per week). Tendons and ligaments feel more resilient under load. Wound healing is visibly accelerated. Scar tissue formation is actively reduced through anti-fibrotic Ac-SDKP signaling at sustained levels.
Weeks 7 to 12: Maintenance Phase. Lower dose maintains angiogenic and anti-fibrotic support without diminishing returns from continued high-dose loading. Most users report sustained recovery improvements and fewer re-injuries. Some cycle off at week 8 if the primary injury is resolved. Others complete the full 12 weeks for chronic or multi-site problems before taking 6 weeks off for receptor sensitivity recovery.
Detailed Timeline: Science vs Community
Tβ4 released by platelets and macrophages at injury sites. Anti-inflammatory effects begin via macrophage modulation and Ac-SDKP domain action. Short IV half-life (~2h) means plasma levels stabilize rapidly with repeated SC dosing. Angiogenic signaling initiates but new vessel formation is not yet established.
Most users experience mild fatigue and occasional flu-like symptoms (days 3–7). Some report reduced localized pain at injury site by end of week 2. Others notice no change yet: loading effects are cumulative.
New blood vessel formation underway at injury sites, increasing nutrient and oxygen delivery. Progenitor cell migration and differentiation in progress. Anti-fibrotic Ac-SDKP domain actively reducing fibroblast activity and scar tissue formation.
Commonly reported: meaningful reduction in injury pain and swelling, improved joint mobility and range of motion, better sleep quality. Some users note surprisingly rapid resolution of previously chronic injuries. Advanced users add that DOMS recovery improves notably.
The Phase II pressure-ulcer trial ran to day 84, and complete healing did not beat placebo (8 of 54 vs 3 of 18, NCT00382174). Cardiac progenitor cell activation at sustained levels. Anti-fibrotic signaling at maximum: scar tissue formation actively attenuated. Transition point to maintenance dosing.
Most users report significant measurable healing progress. Tendon and ligament injuries feel substantially more resilient under load. Wound healing visibly accelerated. Many users transition to maintenance (2 mg 1x/week) at this point.
Reduced dose maintains angiogenic and anti-fibrotic signaling at lower intensity. Science suggests diminishing incremental benefit from continued high-dose loading once acute healing is established. Off-cycle period required to assess recovery.
Most users continue improved recovery rates and reduced re-injury frequency. Some cycle off after week 8 if primary injury is resolved. Others complete 12-week cycle for chronic or multi-site injuries before taking 6 weeks off.
Pharmacokinetics
Source: Phase I IV PK study in healthy volunteers (PMID 20536472): mean half-life ranged from 0.95h (42 mg) to 2.1h (1260 mg), dose-dependent
Pharmacokinetics: Active Dose Over Time
t½ = ~2 hours (IV)Disclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is Thymosin Beta-4 Legal?
Thymosin beta-4 is classified as a research chemical in the United States. It does not hold FDA approval for any therapeutic indication as of October 2026. Thymosin beta-4 is not on the 503A bulks list (21 CFR 216.23) and appears in none of FDA's 503A categories (May 14, 2026). FDA's Category 2 entry was its LKKTETQ fragment (TB-500), which FDA's page lists as withdrawn (current as of April 22, 2026).
Research-grade Tb4 is still sold online, but only a batch-specific third-party COA with mass spectrometry confirms product identity.
Tb4 is prohibited by WADA for competitive athletes.
This content is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. Consult a licensed healthcare provider before using any research peptide.
Evidence grade: Phase 3 trial (Peptide Evidence Gap, October 2026)
Who Should Consider Thymosin Beta-4
- Athletes recovering from soft tissue injuries requiring full-spectrum healing support
- Post-surgical patients seeking accelerated wound healing with reduced scarring
- Individuals with cardiac tissue damage or post-myocardial infarction recovery (preclinical evidence)
- Patients with chronic fibrotic conditions (pulmonary, hepatic, or dermal fibrosis)
- Older adults with impaired wound healing capacity
- Those with corneal injuries or dry eye conditions (ophthalmic formulations studied in trials)
- Individuals recovering from traumatic brain injury (preclinical evidence)
Related Peptides
What Changed for Thymosin Beta-4
- Evidence
Corrected Oct 18, 2026: thymosin beta-4's research stage is phase 3, not 1; RGN-259 eye drops had a published phase 3 (SEER-1), per PubMed (PMID 36613994).
Before: Phase 1 After: Phase 3 (SEER-1, RGN-259 eye drops, PMID 36613994)
What this does not mean: No new study was published, and the dose tiers are unchanged. The phase 3 trials tested RGN-259 eye drops; SEER-1 stopped at 18 patients, short of significance (p=0.0656). ClinicalTrials.gov lists no phase 3 of injected thymosin beta-4.
Source: Int J Mol Sci 2023, 0.1% RGN-259 (thymosin beta-4) ophthalmic solution in neurotrophic keratopathy: randomized, placebo-controlled, double-masked phase III trial (SEER-1; Sosne et al.) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Peptide Schedule Research TeamReviewed Apr 7, 202614 Citations
References
- [1]A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]First-in-human phase I study of recombinant human thymosin beta-4 in healthy Chinese volunteers (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Thymosin beta4 is cardioprotective after myocardial infarction (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Thymosin beta4 and cardiac repair (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Thymosin Beta-4: Roles in Development, Repair, and Engineering of the Cardiovascular System (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Thymosin beta-4: a multi-functional regenerative peptide: basic properties and clinical applications (opens in a new tab)PubMed 22074294PubMed
- Thymosin beta4-sulfoxide attenuates inflammatory cell infiltration and promotes cardiac wound healing (opens in a new tab)PubMed 23820300PubMed
- Recombinant thymosin beta 4 can promote full-thickness cutaneous wound healing (opens in a new tab)PubMed 17923415PubMed
- Thymosin beta-4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial (Sosne et al., Cornea 2015) (opens in a new tab)PubMed 25826322PubMed
- A Randomized, Double-Blind, Placebo-Controlled, Dose Response Study of the Safety and Efficacy of Thymosin Beta 4 in the Treatment of Patients With Pressure Ulcers (NCT00382174) (opens in a new tab)Clinical Trial
- The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients (Ann N Y Acad Sci 2012) (opens in a new tab)PubMed 23050815PubMed
- 0.1% RGN-259 (Thymosin β4) Ophthalmic Solution Promotes Healing and Improves Comfort in Neurotrophic Keratopathy Patients in a Randomized, Placebo-Controlled, Double-Masked Phase III Clinical Trial (SEER-1; Sosne et al., Int J Mol Sci 2023;24(1):554) (opens in a new tab)PubMed 36613994PubMed
- Engineered tandem thymosin peptide promotes corneal wound healing (Nguyen et al., Invest Ophthalmol Vis Sci 2025;66(14):31) (opens in a new tab)PubMed 41235866PubMed
- Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute STEMI after reperfusion (Zhang et al., Cardiovasc Res 2025;121(17):2747-2758) (opens in a new tab)PubMed 41229390PubMed
Related Resources
Related Tools
Storage & Stability
Frequently Asked Questions
How popular is Thymosin Beta-4?
Popular. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 200–500. Community mentions on Reddit: ~200–500 threads (conflated with TB-500).
1,038 papers on PubMed, the US library of medical research. Search them on PubMed (opens in a new tab).
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.